A multi-site, open-label, sequential-group, multiple-ascending-dose study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamic effects of Lu AG13909 in patients with congenital adrenal hyperplasia
Phase 1
Recruiting
- Conditions
- Congenital adrenal hyperplasiaMedDRA version: 20.0Level: LLTClassification code: 10010323Term: Congenital adrenal hyperplasia Class: 10010331Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
- Registration Number
- CTIS2023-503711-15-00
- Lead Sponsor
- H. Lundbeck A/S
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 36
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method